CARDIOVASCULAR [bdsy]
Safety [hcpp]
Estrogens, Conjugated [horm, phsu, strd]
bazedoxifene [orch, phsu]
Meta-Analysis [inpr]
Trial [resa]
objectives [inpr]
Five [qnco]
randomized [resa]
Phase 3 [tmco]
Trial [resa]
Efficacy [qlco]
Safety [hcpp]
Estrogens, Conjugated [horm, phsu, strd]
bazedoxifene [orch, phsu]
treating [topp]
menopausal symptoms [sosy]
Preserving [ftcn]
Bone [bpoc]
Pooled [cnce]
CARDIOVASCULAR [bdsy]
Safety [hcpp]
Estrogens, Conjugated [horm, phsu, strd]
bazedoxifene [orch, phsu]
Methods [inpr]
Pooled [cnce]
CARDIOVASCULAR [bdsy]
Safety [hcpp]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Received [qlco]
Dose [qnco]
CE [idcn]
mg/mg [qnco]
N NOS [aapp, imft]
CE [idcn]
mg/mg [qnco]
N NOS [aapp, imft]
Estrogens, Conjugated [horm, phsu, strd]
bazedoxifene [orch, phsu]
Dose [qnco]
N NOS [aapp, imft]
placebo [topp]
N NOS [aapp, imft]
Five [qnco]
Trial [resa]
Venous [bpoc]
Thromboembolic events [patf]
coronary heart disease [dsyn]
Cerebrovascular [qlco]
Events [evnt]
reviewed [inpr]
Independent [idcn]
Adjudication Committee [prog]
Meta [euka]
Approach [spco]
Venous [bpoc]
Thromboembolic events [patf]
Woman [popg]
Interval [tmco]
Women [popg]
Take [hlca]
CE [idcn]
mg/mg [qnco]
Take [hlca]
CE [idcn]
mg/mg [qnco]
Women [popg]
Take [hlca]
Estrogens, Conjugated [horm, phsu, strd]
bazedoxifene [orch, phsu]
Dose [qnco]
placebo [topp]
Stroke [dsyn]
Woman [popg]
coronary heart disease [dsyn]
Woman [popg]
1-7 [gngm]
Compared [acty]
placebo [topp]
Relative Risk [qnco]
Estrogens, Conjugated [horm, phsu, strd]
bazedoxifene [orch, phsu]
Dose [qnco]
vte [orch]
Stroke [dsyn]
coronary heart disease [dsyn]
Conclusions [idcn]
CE [idcn]
CE [idcn]
mg% [qnco]
mg% [qnco]
Acceptable [qlco]
CARDIOVASCULAR [bdsy]
Safety [hcpp]
Profile [lbpr]
Stroke [dsyn]
coronary heart disease [dsyn]
placebo [topp]
Health [idcn]
postmenopausal [tmco]
Women [popg]
vte [orch]
